Location out of bounds
Radial
Radial

Newsroom

Resources for journalists

All Press Releases
Technician reviews bag of new pathogen reduced platelets.

Versiti among first in U.S. to offer pathogen reduced platelets

Versiti – February 21, 2018

Milwaukee – February 21, 2018 – Versiti, Inc., a national leader in blood health innovation, is among the first in the United States to provide pathogen reduced platelets that reduce the risk of infection and lead to safer transfusions for patients. Versiti produced its first pathogen reduced platelets in January 2018 at BloodCenter of Wisconsin, part of Versiti. The platelets were provided to one of Versiti’s hospital partners in Wisconsin. 

Because platelet transfusions are on the rise due to an increase in trauma situations, transplantation, and in treatment of cancer patients, as well as to prevent and treat bleeding in patients who are thrombocytopenic, the importance of providing pathogen reduced platelets is becoming increasingly important. Versiti, which already utilizes multiple tests and every available technology to ensure the safety of the blood supply, took a leading role in the implementation of pathogen reduction technology.

“Versiti is dedicated to patient and transfusion safety, continually seeking novel technologies that improve the safety of the blood and blood components we distribute and provide to our hospital partners,” said Versiti Chief Medical Officer Thomas Abshire, M.D. “This technology helps advance transfusion medicine and creates improved outcomes for patients receiving platelet transfusions.”  

This innovative technology reduces the risk for infection and disease transmission in transfused patients. By using a special additive, the technology inactivates bacteria, viruses and other pathogens as well as leukocytes that may be present in donated blood. The technology also preserves cell and protein quality, and may offer additional benefits, including platelet shelf-life extension, and negate the requirement for gamma-irradiation and testing for cytomegalovirus of platelets.

Versiti anticipates expanding production of pathogen reduced platelets at its BloodCenter of Wisconsin location, and at all Versiti locations in the near future, to serve additional hospitals throughout the state and across the country.

About Versiti

Versiti, a national leader in blood health innovation, was formed with the mission to improve the health of patients and enable the success of our health care partners nationally. We provide innovative, value added solutions in the fields of transfusion medicine, transplantation, and blood-related diseases to meet the needs of each of our customers. The collective efforts across Versiti result in improved patient outcomes, expanded access to care and cost efficiencies for health care systems nationwide. For more information, visit www.versiti.org.

###

Contact Us

Fay Spano

Director, Public Relations and Corporate Communications
Email (414) 937-6124

Other Press Releases

Bears

Heartland Blood Centers and the Chicago Bears team up for Chicago Community Thanksgiving Blood Drive

November 14, 2018

HBC and the Chicago Bears are teaming up for Chicago Community Thanksgiving Blood Drive on Wednesday, Nov. 21, from 8 a.m. to 2 p.m. at Rauner Family YMCA .

Read More
Stollenwerk Family

Versiti’s Blood Research Institute receives one million dollar gift from Stollenwerk Family

October 25, 2018

Versiti’s Blood Research Institute has announced a one million dollar gift from the Stollenwerk Family Foundation, based in Mequon, Wisconsin.

Read More
Blood Center of Wisconsin Logo

BloodCenter of Wisconsin awarded $5 million NIH glycosciences grant

September 7, 2018

New national training program aims to mainstream glycosciences; train next generation of researchers

Read More
ic-arrow-right
x

This website uses cookies to ensure you get the best experience on our website. Learn more